ENQUIRE PROJECT DETAILS BY GENERAL PUBLIC

Project Details
Funding Scheme : General Research Fund
Project Number : 14168517
Project Title(English) : RAC1 Genomic Alterations Drive Head and Neck Cancer Progression 
Project Title(Chinese) : RAC1基因變化在頭頸癌的病變 
Principal Investigator(English) : Prof Lui, Vivian Wai Yan 
Principal Investigator(Chinese) :  
Department : School of Biomedical Sciences
Institution : The Chinese University of Hong Kong
E-mail Address : vlui002@cuhk.edu.hk 
Tel :  
Co - Investigator(s) :
Dr CHAN, Amy Bik-Wan
Dr Hong, Bo
Dr Lau, Chin-Wang
Dr Li, Ming
Dr Su, Richard Yuxiong
Panel : Biology & Medicine
Subject Area : Medicine, Dentistry & Health
Exercise Year : 2017 / 18
Fund Approved : 1,229,089
Project Status : Completed
Completion Date : 31-8-2021
Project Objectives :
To compare RAC1 genomic alterations in Asian and US HNC patient tumors.
To determine the biological contributions of RAC1 mutations and amplification to HNC growth, invasion, anoikis, tumor-formation and metastasis.
a) To examine the in vitro and in vivo efficacies of PI3K inhibitors in RAC1-mutated HNC models, including RAC1 p.A159V and other RAC1 mutations. b) To elucidate the mechanisms of PI3K/AKT hyperactivation conferred by the hotspot RAC1 p.A159V neomorphic mutation in HNC models.
Abstract as per original application
(English/Chinese):

鑑定癌症基因突變與藥物敏感性可直接影響患者治療的方法。頭頸癌(HNC)缺乏立即可藥用的遺傳事件,妨礙了精準醫藥的發展。在這裡,我們確定了HNC中的RAC1 突變可成為藥物靶點。我們的臨床和臨床前研究結果導致我們假設RAC1基因組畸變是HNC腫瘤發生的直接驅動因素,並且激活RAC1突變可以通過HNC細胞中的新機制誘導PI3K激活。在這裡,我們建議:1)比較亞洲和美國HNC患者腫瘤中的RAC1基因組譜(包括突變和基因拷貝變化),以確定其在2個主要HNC群體中的臨床相關性,其突變特徵,預後活性和潛力性別偏見; 2)確定所有HNC相關RAC1突變的生物學貢獻,並擴增HNC生長,侵襲,抗氧化,抗腫瘤形成;和3)檢查PI3K抑製劑敏感性,及其機制。這項研究 可以帶動HNC 靶向臨床精確治療 及 提供其遺傳基礎(潛在有益於> 16,200 HNC患者/年)。
Research Outcome
Layman's Summary of
Completion Report:

  SCREEN ID: SCRRM00542